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Abstract In vertebrates and bacteria, heparosan the pre-
cursor of heparin is synthesized by glycosyltransferases via
the stepwise addition of UDP-N-acetylglucosamine and
UDP-glucuronic acid. As heparin-like molecules represent
a great interest in the pharmaceutical area, the cryptic
Pasteurella multocida heparosan synthase PmHS2 found to
catalyze heparosan synthesis using substrate analogs has
been studied. In this paper, we report an efficient way to
purify PmHS2 and to maintain its activity stable during
6 months storage at −80°C using His-tag purification and a
desalting step. In the presence of 1 mM of each nucleotide
sugar, purified PmHS2 synthesized polymers up to an
average molecular weight of 130 kDa. With 5 mM of UDP-
GlcUA and 5 mM of UDP-GlcNAc, an optimal specific
activity, from 3 to 6 h of incubation, was found to be about
0.145 nmol/μg/min, and polymers up to an average of
102 kDa were synthesized in 24 h. In this study, we show
that the chain length distribution of heparosan polymers can
be controlled by change of the initial nucleotide sugar
concentration. It was observed that low substrate concen-
tration favors the formation of high molecular weight
heparosan polymer with a low polydispersity while high
substrate concentration did the opposite. Similarities in the
polymerization mechanism between PmHS2, PmHS1, and
PmHAS are discussed.
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Introduction
Bioactive carbohydrates play an important role in many
organisms. In vertebrates, they are implicated in many
physiological processes and biological functions at the
molecular level from gene expression to protein regula-
tion and interaction (Jackson et al. 1991). Therefore,
some of these carbohydrates, especially glycosaminogly-
cans (GAGs), are of great interest in medicine. GAGs are
linear polysaccharides, sulfated or not, made of repeated
disaccharides units of hexose or hexuronic acid and N-
acetyl-hexosamine. The GAG heparosan (-α4-GlcNAc-
β1,4GlcUA-1-) is the unsulfated precursor of heparin.
Heparin acts as an anticoagulant and is known for its use
in surgery to prevent, e.g., vein thrombosis (reviewed in
Rabenstein 2002). Recent studies have evidenced that the
molecular weight of heparin greatly influences its biolog-
ical activity. Low molecular weight heparin (LMWH)
ranging from 2.4 to 5.4 kDa (8 to 18 monosaccharides
units) may have an antitumor effect by reducing or
suppressing tumor growth and metastasis in some cases
(Castelli et al. 2004; Lee 2007; Norrby 2006). This finding
implies that a tight control of the molecular weight of
heparin and heparin-like molecules during production
seems to be the clue to enlarge its therapeutic use.
However, the current ways to produce heparin and
LMWH are far from being optimal with respect to the
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control of the chain length distribution. Monodisperse
heparin fractions with low molecular weight are difficult to
obtain from animal tissue, and the chemical synthesis of
polymers longer than six units is not economically feasible
(Chen et al. 2006).
In vivo GAGs are polymerized by glycosyltransferase
(GT) enzymes that catalyze the polymer elongation through
stepwise addition of α-linked uridine nucleotide sugars.
Depending on the polysaccharide structures, the polymer-
ization involves GT able to perform an inverting (α→β) or
a retaining (α→α) mechanism (Coutinho et al. 2003). The
polymerization step involving the (α→β) mechanism is
well known, however, the mechanism (α→α) is less
described and still remains not fully understood. Due to
the nature of the heparosan polymer, the heparosan
synthase exhibits both of these mechanisms to elongate
heparosan chains.
Bacterial capsules composed of heparosan have been
reported in Escherichia coli K5 (Vann et al. 1981) and
Pasteurella multocida Type D (DeAngelis et al. 2002;
Pandit and Smith 1993; Rimler 1994). In E. coli K5, the
synthesis of heparosan is regulated by four genes, KfiA,
KfiB, KfiC, and KfiD, located on the same operon.
However, only two of them, KfiA and KfiC, encoding
respectively for the N-acetylglucosaminyltransferase and
for the D-glucuronyltransferase seem to be involved in the
elongation of heparosan polymers (Chen et al. 2006;
Griffiths et al. 1998; Hodson et al. 2000). Different from
what is observed in E. coli, in P. multocida Type D, the
synthesis of heparosan is performed by only one enzyme
with two glycosyltransferase activities; the heparosan
synthase PmHS1. The P. multocida Type D heparosan
synthase gene pmhssA also known as pmhs1 located on the
putative capsule locus was cloned, and PmHS1 active
proteins were expressed (DeAngelis and White 2002).
Based on homology with pmhssA, a cryptic gene pmhssB
(described also as pglA) encoding for an active recombi-
nant heparosan synthase PmHS2 was discovered in P.
multocida Type A, D, and F (DeAngelis and White 2002;
May et al. 2001). Characterization of recombinant PmHS1 and
PmHS2 enzymes showed that despite their high amino acid
level homology (73%), the enzymes differ considerably with
respect to their kinetic properties and the molecular weight
distribution of the synthesized heparosan polymers (DeAngelis
and White 2004; Sismey-Ragatz et al. 2007).
Kinetic studies on both P. multocida heparosan synthase
enzymes report an initiation rate and an elongation rate of
2.6 and 76 pmol/μg/min, respectively, for PmHS1, while
5.2 and 28 pmol/μg/min were observed for PmHS2
(Sismey-Ragatz et al. 2007). When incubated without
acceptor, the polymerization properties of PmHS1 and
PmHS2 were largely different with respect to molecular
weight of the synthesized polymer. PmHS1 synthesized
heparosan polymers with an average molecular weight of
800 kDa, while heparosan of 28 kDa were observed when
PmHS2 was used as a catalyst. The addition of heparosan
oligosaccharide acceptors lowered the molecular weight of
heparosan polymers synthesized by PmHS1 while it had
almost no effect on the PmHS2 polymerization process.
Sismey-Ragatz et al. (2007) also showed that contrary to
PmHS1, PmHS2 is able to synthesize glycosaminoglycan
polymers with new biological properties using unnatural
donor sugar analogs. These heparin analog molecules with
potentially new biological activities represent a great
interest to enlarge therapeutic uses. It was indeed observed
that depending on the sugar substitution, digestion of the
polymer by heparinase III could be avoided (Sismey-Ragatz
et al. 2007).
Because of the above-mentioned polymerization prop-
erties, PmHS2 was investigated in detail in this study. An
efficient way to express, purify, and store the PmHS2
enzyme is reported. The PmHS2 polymerization activity
in time as well as the heparosan polymer elongation
process has been characterized by use of a coupled
enzyme assay, agarose gel electrophoresis, and high-
performance size-exclusion chromatographic (HPSEC)
analysis. The influence of parameters such as the
nucleotide sugar, the cofactor, and the UDP concentra-
tions on the enzyme activity and the product molecular
weight are described. In this report, we show that PmHS2
is capable of synthesizing heparosan polymers with a high
molecular weight (Mw) and that heparosan polymer
average Mw and size distribution can be controlled by
the initial nucleotide sugar concentration present in the
polymerization reaction.
Materials and methods
Cloning, expression, and purification of recombinant
P. multocida heparosan synthase 2
Based on the sequence of the P. multocida Type D
heparosan synthase cryptic gene pmhssB (GenBank ac-
count number AY292200), the pmhssB forward primer
CGCCATGAAGGGAAAAAAAGAGATG and reverse
primer GGATCCTTATAAAAAATAAAAAGGTAAAC
were designed. Using a high-fidelity polymerase chain
reaction (PCR) mix (Roche) on genomic DNA isolated
from a P. multocida Type D (strain number: 40456 from the
Wageningen-UR Central Veterinary Institute collection), the
pmhssB open reading frame was amplified by 30 cycles of
PCR (94°C, 30 s; 60°C, 30 s; 72°C, 1 min). The PCR
fragment was ligated into pCR-BluntII vector and trans-
formed into E. coli Top10 cells (Invitrogen). The identity of
the pmhssB gene was confirmed by sequencing (Base Clear
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B.V). Using the forward primer CACCATGAAGGGA
AAAAAAGAGATG and the reverse primer TAAAAAA
TAAAAAGGTAAACAGGGGATA, pmhssB fragments
were obtained by applying 30 cycles of PCR (94°C, 30 s;
55°C, 30 s; 72°C, 1 min) which were cloned in the
pET101-D-TOPO expression vector (Invitrogen).
The pET101-D-TOPO vector allowing the fusion of a
V5 epitope and a C-terminal His-tag to the pmhssB
fragment was first transferred into the E. coli Top10.
Subsequently, positive plasmids were isolated and trans-
formed into the E. coli BL21*(DE3) expression strain
(Invitrogen). Recombinant protein was expressed according
to the manufacturer's instruction. Briefly, a culture inocu-
lated with an overnight preculture was grown in LB
ampicillin (50 μg/ml) media at 37°C under shaking
condition (250 rpm). When the optical density600 (OD)
was around 0.6, the protein expression was induced by
addition of 0.5 mM isopropyl b-D-1-thiogalactopyranoside,
and growth was continued for 2 h at 30°C/250 rpm. Cells
were harvested by centrifugation (Allegra 6R centrifuge,
Beckman Coulter, Rotor: GG-3.8A.) at 5°C/3,000 g/20 min,
and the pellet was stored at −80°C. For enzyme purification,
the pellet (from 75 ml culture) was thawed on ice and
resuspended in 4 ml phosphate buffer (50 mM NaH2PO4 and
300 mM NaCl, pH 8) before being sonicated 4×30 s on ice
with a sonication tip (Vibra cell, Sonic and materials, Inc,
output control set on 40). Prior to centrifugation at 5°C/
18,000 g/15 min (Eppendorf centrifuge 5417R), MgCl2 was
added to the lysate to a final concentration of 6 mM (Kane et
al. 2006). After centrifugation, the supernatant was kept
on ice for further purification, and the pellet was
discarded. In order to perform an optimal His-tag
purification, imidazole was added to the supernatant to a
final concentration of 10 mM. To 4 ml of supernatant,
1 ml of 50% Ni-NTA Superflow resin slurry (Qiagen) was
added and gently mixed for 1 h at 4°C on a rotating
shaker. The resin slurry and supernatant mix was washed
with increasing imidazole concentrations, respectively,
10 mM and 20 mM. To allow the elution of PmHS2,
250 mM of imidazole was present in the elution buffer.
The first three eluted fractions of 1 ml known to have the
highest PmHS2 concentrations were pooled and then
desalted by gel filtration using a PD10 column with
Sephadex G-25 Medium resin (GEA Healthcare) with
50 mM Tris pH7.2 as eluent. Ethylene glycol to a final
concentration of 1 M was added to the desalted PmHS2
fraction before storage at −80°C.
Purity of the PmHS2 desalted fraction was monitored by
10% sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) stained with SimplyBlue SafeStain
(Invitrogen), and the protein content was quantified by the
bicinchoninic acid (BCA) method (Pierce) using bovine
serum albumin as reference.
Characterization of the PmHS2 polymerization process
Standard polymerization conditions
Unless noted, polymerization assays with a final volume
between 30 to 200 μl contained 40 mM Tris pH7.2, 4 mM
MnCl2, 4 mM MgCl2, 5 mM UDP-glucuronic acid, 5 mM
UDP-N-acetylglucosamine, and 55–60µg/ml of 95% pure
PmHS2 enzyme. The reaction occurred in the dark at 30–
32°C under mild shaking conditions for time ranging from 1.5
to 48 h depending on the experiment. In order to study the
effect of different parameters, the composition of the polymer-
ization mix was changed. Modifications in the standard
incubation conditions are stated in the legend to the figures.
Note that in this study, no oligosaccharide acceptor was
added to the polymerization reaction.
Determination of the heparosan polymer molecular weight
and polydispersity
After synthesis, the reactions were quenched at 99°C for
10 min and then cooled on ice. The polymer chain length
and the molecular weight distribution of the synthesized
products were assessed by agarose gel electrophoresis and
by HPSEC analysis. For gel analysis ,the samples were
mixed with glycerol to a final concentration of 12%, loaded
on a 2% agarose gel, and run for 2 h at 50 V in Tris-acetate
EDTA buffer (Lee and Cowman 1994). The gels were
stained overnight in the dark in 50% ethanol per 0.005%
Stains-All (Sigma). The destaining of the gels was carried
out in pure water for 30 min in the dark followed by an
exposure to the light till background discoloration. Images
from the gel were acquired with a BioRad GS-800
calibrated densitometer and analyzed by the Quantity One
program. Selected hyaluronan molecular weight marker
ranging from 27 to 495 kDa (Select-HALoLadder, Hyalose,
OK, USA) was used to estimate the heparosan molecular
weight. Since Stains-All tends to overstain the polysac-
charides on an agarose gel, it was difficult to estimate the
average molecular weight of the polymers in an accurate
way by this type of analysis.
Alternatively, the size distribution and the molecular
weight of the polymers were analyzed by HPSEC on a
SpectraSystem HPLC (Thermo Separation Products, USA)
using three TosoHaas TSK-gel columns in series (4,000,
3,000, and 2,500 PWx1, 300×7.5 mm; TosoHaas, Japan)
preceded by a TSK PWx1 guard column (TosoHass, Japan).
Samples (20 μL) were injected and eluted at 30°C using
0.8 ml/min NaNO2 (0.2 M). Detection was performed using
a Shodex RI 71 refractive index detector (Showa Denko K.
K., Japan). Hyaluronan molecular weight standards of,
respectively, 30, 160, and 262 kDa were used for calibration.
From the logarithmic model fitting the elution time of the
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hyaluronan molecular weight standards, we established the
following equation: Mw ¼ Mi ¼ exponential elutiontimeð½
27:811Þ= 1:4765ð Þ. By assuming that heparosan and
hyaluronan elution patterns are comparable, the molecular
weight of the eluted samples (Mi) was determined by
applying the equation mentioned above. The molecular
weight distribution (polydispersity index (PDI)) was deter-
mined using the following formula: ½Formula and equations
found in Materials and methods section The variables or
qualifiers have been changed for consistency: Please check
if appropriate: PDI ¼Mw=Mn
Mn ¼
P
i NiMið ÞP
i Nið Þ
Mw ¼
P
i NiMi2
 
P
i NiMið Þ
The refractive index (RI) signal, known to be proportional to
the relative amount of eluted product, was considered as being
equivalent to the amount of polymer chains (Ni) of molecular
weight Mi.
Determination of PmHS2 specific activity
The polymerization reaction was performed with 95% pure
PmHS2 and in presence of nucleotide sugars. Both
nucleotide sugars (UDP-glucuronic acid and UDP-N-
acetylglucosamine) were added in equimolar ratio and in
sufficient amount in order to initiate the polymerization and
enable us to follow the elongation process in time by means
of the coupled enzyme assay and agarose gel analysis. The
activity of PmHS2 was assessed by measuring the UDP
formation with a noncontinuous spectrophotometric assay
at 340 nm (Gosselin et al. 1994; Krupa et al. 2007). In this
assay, the UDP released from the conversion of the
nucleotide sugars during the polymerization is coupled via
pyruvate kinase (PK) and lactate dehydrogenase (LDH) to
the oxidation of NADH into NAD+. With 0.3 mM NADH
as initial concentration and in presence of UDP, the NADH
conversion into NAD+ was established to be linear.
According to the stoichiometric equation, 1 mM UDP will
convert 1 mM NADH. This was confirmed with prelimi-
nary experiments in which the NADH/UDP conversion
ratio was found to be 1.016.
Due to the degradation of nucleotide sugars at high
temperature, heat shock was not used to quench the
reactions. Polymerization reactions were stopped by
immersion in liquid nitrogen and stored at −20°C. Prior
to the UDP measurement, the samples were thawed on
ice and diluted to contain less than 0.3 mM of UDP. No
residual PmHS2 activity was detected using this proce-
dure. The following compounds were added to the
diluted samples: 0.3 mM NADH, 2 mM phospho(enol)
pyruvic acid trisodium salt heptahydrate 98% (Across
Organic, Belgium), 112.5 mM KCl, and 25 U/ml LDH
(L-lactate dehydrogenase from Rabbit muscle, Fluka).
The mix with a final volume of 140 μl was preincubated in a
Tecan Safire thermostated spectrophotometer during 10min at
30°C, and its absorbance was measured at 340 nm. The assay
was performed in microtiter plate wells (UV-star plate 96
wells, flat bottom, Greiner Bio-One). After the preincubation,
PK (pyruvate kinase from rabbit muscle, Sigma) was added to
a final concentration of 10 U/ml. The final reaction volume
was 150 μl. The OD was measured at 340 nm for 30 min at
30°C. A stable absorbance indicated full conversion of the
UDP. The preincubation and incubation absorbance data were
combined to calculate the amount of UDP released in the
polymerization reactions and thus, estimate the enzymatic
activity using the conversion ratio of 1.016. All experiments
were performed in independent duplicate, and the average is
presented in the “Results” section.
Identification of the polymer chains synthesized by PmHS2
The identification of the polymer obtained by enzymatic
activity of the recombinant PmHS2 was carried out using
Heparinase III from Flavobacterium heparinum (Sigma).
Heparinase III is known to specifically cleave at the α1–4
linkage between the hexosamine and glucuronic acid
residues of heparosan and heparan sulfate. First, the
polymerization assay was quenched at 99°C for 30 min,
then Heparinase III (0.5 U/μl in 0.05 M sodium phosphate
buffer pH7.6) was added to it, and the mixture was
incubated for 24 h at 30°C (DeAngelis et al. 2002). The
samples obtained after polymerization and incubated with
and without Heparinase III were analyzed on a 2% agarose
gel. Full degradation of the polymer confirmed the identity
of PmHS2 synthesized product as being heparosan poly-
mers (data not shown).
Results
Cloning, expression, and purification of the recombinant
P. multocida heparosan synthase PmHS2
The P. multocida pmhssB gene was cloned, and PmHS2
recombinant proteins were expressed using the vector
pET101 in E. coli BL21*(DE3) strain. After sonication of
the cell suspension, 15–20% of PmHS2 protein was found in
the soluble fraction (Fig. 1). Most of the PmHS2 remained
in the membrane fraction. After Ni-NTA purification and
PD10 desalting steps, we estimated the purity of PmHS2
enzyme to be about 95% based on SDS-PAGE gel analysis.
BCA assay showed that 5% to 10% of pure PmHS2 enzyme
was lost during the PD10 desalting step. We estimated that
about 7±1 mg of 95% purified PmHS2 was obtained from a
1 L of E. coli culture after 2 h of induction at 30°C.
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Characterization of the PmHS2 polymerization process
Storage stability of PmHS2
The storage stability of PmHS2 was determined by comparing
the catalytic activity of the newly extracted and purified
PmHS2 enzyme with the PmHS2 enzyme stored at −80°C.
The catalytic activity of PmHS2 was estimated by gel
electrophoresis analysis of the polymerization products
obtained under standard conditions. Addition of MnCl2 and
MgCl2 to the storage buffer increased enzyme instability at
−80°C. Under these storage conditions, a significant loss of
activity was observed after 3 weeks at −80°C. Addition of
ethylene glycol to a final concentration of 1 M in the storage
buffer was crucial to ensure the enzyme stability. With
ethylene glycol, both the activity of the enzyme expressed as
the amount of nucleotide sugars converted by PmHS2 after
24 h of incubation at 30°C and the chain length of the
synthesized heparosan were the same before and after
6 months at −80°C (Fig. 2). After 1 year of storage, a
decrease of about 10% to 20% of the enzymatic activity was
observed. SDS-PAGE analysis showed that PmHS2 was not
degraded during the storage at −80°C (data not shown).
Process stability during the polymerization
In presence of 55–60 μg/ml of 95% pure PmHS2 and
20 mM of each UDP-sugar, we observed that PmHS2
maintained at least 80% of its initial activity during the
incubation time from 24 to 48 h. After 24 h of incubation in
the presence of 5 mM or 20 mM of both UDP-sugars,
PmHS2 converted comparable amount of nucleotide sugars.
Based on these results, we assumed that PmHS2 process
stability was constant for 24 h under the assay conditions
used. Thus, we considered 24 h of incubation as being the
reference time point to study the influence of different
parameters such as the divalent metal ion, the nucleotide
sugar, and the UDP concentrations on the polymerization
activity.
Influence of the divalent metal ions Mn2+ and Mg2+
Divalent metal ions such Mn2+and Mg2+ have been
described as being cofactors of some glycosyltransferases
(Markovitz et al. 1959; Stoolmiller and Dorfman 1969).
DeAngelis and White showed that in the case of PmHS2,
Mn2+ is the optimal divalent metal ion to support the
polymerization, but Mg2+ also contributes to the substrate
conversion (DeAngelis and White 2004). To study the
influence of these divalent metal ions on the PmHS2
catalytic activity, an equimolar mixture of MnCl2 and
MgCl2 ranging from 0 to 16 mM was investigated (Fig. 3).
The polymerization was not initiated in absence of metal
cofactor. PmHS2 activity after 24 h of reaction time was
optimal with 4 mM of both MgCl2 and MnCl2. With
0.5 mM of MgCl2 and 0.5 mM of MnCl2, a 40% decrease
of the activity was found. In the range from 2 to 6 mM of
each divalent metal ion, a decrease of activity of not more
than 10% was observed. In presence of 8 to 16 mM of each
divalent metal ion, a decrease of activity, respectively,
about 20% to 50% was observed. Not only the amount of
substrate converted in 24 h was affected by the cofactor
concentrations but also the average polymer molecular
weight. Based on agarose gel electrophoresis analysis,
PmHS2 incubated in presence of 4 mM of Mg2+ and
4 mM of Mn2+ synthesized heparosan polymers with an
Fig. 1 SDS-PAGE analysis of
recombinant PmHS2 protein. E.
coli protein fractions were sepa-
rated on a 10% polyacrylamide
gel and stained with SimplyBlue
SafeStain (Invitrogen). The
expressed PmHS2 is present in
the total E. coli cell fraction
(dilution×4; lane1), in the solu-
ble fraction after cold sonication
and centrifugation (dilution×2;
lane2), and in the His-tag puri-
fied and PD10 desalted fraction
(dilution×1; lane3). The ap-
proximate protein molecular
weight (around 77 kDa) was
estimated by comparison with
the SeeBlue Plus2 Prestain
(Invitrogen) molecular mass
standard (lane 4)
Fig. 2 Influence of the time of storage at −80°C on PmHS2
polymerization activity. After several months of storage at −80°C,
purified PmHS2 (55–60 μg/ml) was thawed on ice, and its activity
was assayed in the standard polymerization buffer described in the
Materials and methods section. Enzyme activity expressed as the
amount of substrate converted after 24 h of incubation at 30°C was
determined using the coupled enzyme assay. One hundred percent
activity corresponds to the amount of substrate converted by freshly
extracted enzyme
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average of 102 kDa while 30–40 kDa heparosan polymers
were obtained in presence of 10 mM of each ion.
Influence of the nucleotide sugar concentrations
Since for each mole of nucleotide sugar converted 1 mol of
UDP is released, the free UDP generated during the
polymerization reaction was used to estimate the substrate
conversion by PmHS2. The molecular weight and the size
distribution of heparosan polymer were determined by
agarose gel electrophoresis and HPSEC using hyaluronan
polymers with Mw ranging from 27 to 495 kDa as
standards.
Nucleotide sugars, UDP-GlcUA, and UDP-GlcNAc,
mixed in an equimolar ratio, were added to the polymer-
ization buffer in a sufficient amount to initiate the
polymerization and enable us to follow the elongation
process in time by means of the coupled enzyme assay and
agarose gel analysis. In order to study the influence of the
nucleotide sugar concentration on the polymerization
process, substrate concentrations of 1, 5, and 20 mM of
both UDP-GlcUA and UDP-GlcNAc were added to the
polymerization reaction with purified PmHS2.
It is important to notice that for the three equimolar
nucleotide sugar concentrations chosen in this study, the
specific activity of PmHS2 remained constant from 180 to
360 min (3 to 6 h) of incubation despite the decrease of
available nucleotide sugars and the subsequent increase in
UDP, a possible inhibitor of the polymerization reaction
(Fig. 4) (Baggenstoss and Weigel 2006; Tlapak-Simmons et
al. 2004).
We observed that the substrate concentration influenced
PmHS2 polymerization process in two distinct manners.
First, as shown in Fig. 4, the substrate concentration
influenced the specific activity of the enzyme. The highest
activity of 0.145 nmol/μg/min was observed between 180
to 360 min of incubation when 5 mM of each UDP-sugar
were added. Adding 20 mM of each nucleotide sugar
lowered PmHS2 specific activity to 0.128 nmol/μg/min. At
a lower substrate concentration, 1 mM of UDP-GlcUA and
1 mM of UDP-GlcNAc, the specific activity was about
0.080 nmol/µg/min. In this last case, based on the amount
of substrate converted per unit of time, we calculated that
the nucleotide sugars were totally converted after about 8 h
of incubation.
Secondly, the substrate concentration greatly influenced
the molecular weight and the size distribution of the
heparosan polymers synthesized by PmHS2. Both agarose
gel electrophoresis and HPSEC analysis showed that
PmHS2 elongated high molecular weight heparosan poly-
mers when incubated in presence of 1 mM of each
nucleotide sugar while lower molecular weight products
were obtained when incubated with 5 mM or 20 mM of
each UDP-sugar (Fig. 5a, b). Also, the polydispersity of the
formed heparosan was influenced by the UDP-sugar
concentration, a low substrate concentration resulted in a
lower polydispersity. HPSEC analysis showed that in
presence of 1, 5, and 20 mM of both UDP-GlcUA and
UDP-GlcNAc, the average molecular weight of the hepar-
osan formed was, respectively, 130, 102, and 45 kDa.
These data showed an inverse correlation between the
nucleotide sugar concentration and the polymer chain
length. Depending on the initial conditions, PmHS2
lengthened heparosan chains to a different polymerization
degree. In presence of 1 mM of each nucleotide sugar,
polymers with an average of 650 monosaccharide units
Fig. 4 Influence of the substrate concentration on PmHS2 activity
during 180 to 360 min of incubation. Purified PmHS2 (55–60 μg/ml)
was assayed in the standard polymerization buffer described in the
Materials and methods section with increasing substrate concentration
ranging from 1 up to 20 mM of both nucleotide sugars. The specific
activity observed during 180 to 360 min of incubation for the
following substrate concentrations 1 (Δ), 5 (○), and 20 mM (•) of
both UDP-GlcUA and UDP-GlcNAc was, respectively, about 0.080,
0.145, and 0.128 nmol/µg/min
Fig. 3 Effect of the MnCl2 and MgCl2 concentration on PmHS2
activity. Enzymatic activity of purified PmHS2 (55–60 μg/ml) was
assayed in the standard polymerization buffer described in the
Materials and methods section with an equimolar mixture of divalent
metal ions (MnCl2 and MgCl2) ranging from 0 to 16 mM. One
hundred percent activity corresponds to the amount of substrate
converted after 24 h of incubation at 30°C in presence of 4 mM of
MnCl2 and 4 mM of MgCl2. The data represent the average of three
independent experiments±standard deviation (SD)
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were synthesized in comparison to 225 monosaccharide
units per polymer with 20 mM of each UDP-sugar.
Table 1 shows, for each substrate concentration studied,
the relation between the amount of nucleotide sugars
converted after 3 h of incubation and the corresponding
average polymer molecular weight observed on agarose gel
electrophoresis. From these data, we have calculated the
amount of heparosan polymer chains present in each
sample and their elongation rates.
The following equation was used to determine the
amount of heparosan polymer chains (nmole PTn) initiated
during the first 3 h of incubation in a 100-μl reaction
volume per microgram of PmHS2.
nmolePTn ¼ mnucleotide sugar at TnMwaverage at Tn
During the first 3 h of polymerization, we calculated that
about nine times less heparosan polymer chains were initiated
and elongated with 1 mM of UDP-GlcUA and 1 mM of UDP-
GlcNAc compared to 20 mM of both UDP-sugars.
Assuming that only the oligosaccharides present after
3 h of polymerization reaction will be elongated, in other
words by neglecting the initiation of new polymers, we
calculated the elongation rate per polymer chain. For this
calculation, the PmHS2 specific activity values previously
determined for a period of incubation between 3 to 6 h were
used (Fig. 4).
At an incubation time Tn, we estimated the total amount
of nucleotide sugar converted (nmole TTn).
nmole TTn ¼ Tn  T nxð Þ
  specific activity
þ nmole TT nxð Þ
For each incubation time Tn, the average polymerization
degree for each polymer chain could be determined (DPTn).
DPTn ¼ nmoleTTn=nmolePTn
From the DPTn, the average Mw of the heparosan
polymer chains at Tn could be assessed.
MwTn ¼ DPTn Mwmonosaccharide
The average number of monosaccharide units transferred
per minute and per heparosan polymer chain (UMS, equal to
elongation rate) has been estimated for the elongation phase
using the equation:
UMS ¼
MwTn MwT nxð Þ
 
Mwmonosaccharide
Tn  T nxð Þ
The calculated elongation rate was about 3.6 monosac-
charide unit per minute per heparosan chain versus 0.6
monosaccharide unit per minute per heparosan chain,
respectively, with 1 mM versus 20 mM of each UDP-
sugar. Thus, at low substrate concentration, both a decrease
in number of polymer chains and an increase in elongation
rate per heparosan chain result in longer polysaccharides.
Finally, based on our assumptions and the calculations, we
determined the average heparosan polymer Mw (kilodaltons)
that should be synthesized after 6 h of polymerization.
MwaverageTn ¼ DPTn Mwmonosaccharide
We were able to describe PmHS2 polymerization
behavior in presence of different substrate concentrations.
However, the calculated average heparosan Mw after 6 h of
incubation are higher than what is observed on agarose gel
electrophoresis (Table 1). For example, in presence of
1 mM of each UDP-sugar, we calculated that after 6 h of
incubation heparosan polymers should have an average
molecular weight of 198 kDa, while on agarose gel
Fig. 5 Influence of the substrate concentration on PmHS2
polymerization process. Purified PmHS2 (55–60 μg/ml) was
incubated at 30°C in the standard polymerization buffer described
in the Materials and methods section with increasing substrate
concentration (UDP-GlcUA and UDP-GlcNAc). a Heparosan
polymer chain length and size distribution depending on the
substrate concentration and incubation time was analyzed on 2%
agarose gels stained with Stains-All. b HPSEC analysis of the
synthesized heparosan after 24 h of incubation in presence of 1, 5,
and 20 mM of both UDP-GlcUA and UDP-GlcNAc. The average
molecular weight (Mw) and polydispersity (PDI) of heparosan
polymers were, respectively, 130 kDa (PDI=1.04; Δ), 102 kDa
(PDI=1.36; ○), and 45 kDa (PDI=1.52)
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heparosan polymers of about 120±10 kDa were observed.
The difference between the calculated and the observed
data is even more significant if we consider 24 h of
incubation. The increased tailoring of the spots (Fig. 6b)
indicated enhanced polydispersity due to initiation of new
heparosan chains at the same time as the elongation of
heparosan polymers.
To conclude, the effect of the nucleotide sugar concen-
tration on PmHS2 polymerization process can be described,
thanks to equations estimating the amount of polymer
chains initiated and their approximate molecular weight.
However, the results suggest that the estimation can be
further improved when taking into account that, during the
elongation, the initiation of new polymer chain occurs.
PmHS2 polymerization process in time
The polymerization process in time was investigated with
55–60 μg/ml of 95% pure PmHS2 using the optimal
nucleotide sugar concentrations to get the highest specific
activity (5 mM of each UDP-sugar). The quantification of
free UDP was used to determine the amount of nucleotide
sugar converted in time. We observed that the PmHS2
polymerization process could be divided into phases
depending on the specific activity observed in time
(Fig. 6a). These polymerization phases have been studied
and characterized for the enzyme-specific activity, the
product molecular weight synthesized, and the polymer
size distribution. The polymerization starts with the
synthesis of short oligosaccharide from nucleotide sugars.
This phase called initiation is quite short, and in the case of
PmHS2, “the level of de novo initiation” is low (Sismey-
Ragatz et al. 2007). As shown in Table 1, we observed a
correlation between the UDP-sugar concentrations and the
amount of heparosan polymer chain initiated.
Following the initiation, the short heparosan chains
synthesized will be elongated. This phase is usually referred
as the elongation phase and is characterized by a constant
ratio of nucleotide sugar conversion over the time (∆P/∆T).
Between 2 and 12 h of incubation, the enzyme specific
activity was about 0.100±0.01 nmol/μg/min (Fig. 6a.). This
corresponds to a transfer of 1.2 monosaccharide unit per
minute per heparosan chain. The average molecular weight
of representative polymer samples increased significantly in
time from 61 kDa (PDI=1.25) after 4 h to 102 kDa (PDI=
1.36) after 24 h of incubation; meaning that about 500
monosaccharide units in average have been incorporated
into each polymer chain. However, as noticed before the
increase in polydispersity in time showed that initiation of
new chains and elongation proceed simultaneously
(Fig. 6b).
The last phase observed is characterized by a sudden
level off of the enzyme activity. After about 12 to 13 h of
incubation, the specific activity of PmHS2 slowed down to
about 0.020±0.005 nmol/μg/min (Fig. 6a). Between 12 and
24 h, the polymer size only slightly increased in contrast
with an increase in polydispersity (Fig. 6b).
Inhibition of the PmHS2 polymerization process by UDP
UDP has been reported to inhibit glutathione 5-transferase
enzymes activity (Baggenstoss and Weigel 2006; Markovitz
et al. 1959; Stoolmiller and Dorfman 1969; Tlapak-
Simmons et al. 2004). When added to the polymerization
buffer prior to the synthesis, UDP showed severe inhibition
of the PmHS2 activity. The inhibition level of 5 mM of
UDP on the polymerization activity was around 50% with
5 mM or 20 mM of each nucleotide sugar (Fig. 7a). In the
range of 8 to 10 mM of UDP, the level of inhibition was
dependent on the nucleotide sugar concentration (Fig. 7b).
With 5 mM of each nucleotide sugar, the complete
inhibition of the PmHS2 polymerization activity was
observed in presence of 8 mM UDP, while with 20 mM
of each nucleotide sugar, the full inhibition was obtained
Table 1 Influence of the nucleotide sugar concentration on the PmHS2 polymerization process
UDP-
GlcUA
UDP-
GlcNAc
(mM)
UDP-sugar converted
per microgram
PmHS2 (nmol; 3h
incubation)
Observed average
heparosan Mw
(kDa; 3h
incubation)a
Heparosan chain
initiated per microgram
PmHS2 (nmol; 3h
incubation)
Calculated
UMS
b
Calculated
average heparosan
Mw (kDa; 6h
incubation)
Observed average
heparosan Mw
(kDa; 6h
incubation)a
1 8±0.20 70±5 0.022 3.6 198 120±10
5 11±0.70 28±2 0.082 1.8 84 60±5
20 10±0.50 10±2 0.200 0.6 33 25±2
The polymerization reaction was performed in 100-μl reaction volume containing 55–60 μg/ml purified PmHS2. The detail of the calculation is
presented in the Results section
a The polymer average molecular weight (± estimated error) was determined using agarose gel electrophoresis analysis in comparison with
hyaluronan molecular weight marker as a reference
b Refers to the calculated average number of monosaccharide units transferred per minute and per heparosan polymer chain
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with 10 mM of UDP. These results suggest that UDP
inhibition is somehow related to the concentration of
nucleotide sugars present in the reaction assay. The
inhibitory UDP concentration does not seem to be reached
during the first hours of incubation. We, indeed, observed
that from 2 to 12 h of incubation, the UDP rise, and the
decrease of substrate availability did not affect PmHS2
specific activity (Fig. 4 and Fig. 6a). To conclude, the
inhibition by UDP does not seem to occur when the UDP
concentration is below or equal to 4 mM.
Discussion
In this report, we describe the successful cloning of the P.
multocida Type D heparosan synthase-2 gene (pmhssb) and
the expression of the corresponding PmHS2 protein into E.
coli BL21*(DE3) using pET101 as an expression vector.
Protein expression and purification allowed the recovery of
7±1 mg of 95% pure and active PmHS2 enzyme per liter of
culture. This level of PmHS2 enzyme recovery after
purification, which is stable for at least 6 months when
stored at –80°C, has not been described so far.
We found that, in absence of divalent metal ions, PmHS2
did not exhibit activity and that cofactor concentration added
in excess inhibit the enzymatic activity. The optimal cofactor
concentration for PmHS2 polymerization activity was deter-
mined to be 4 mM of both Mn2+ and Mg2+. This finding
support the classification reviewed by Coutinho et al. (2003),
PmHS2 belongs to the GlycosylTransferase-A (GT-A)
superfamily due to the requirement for divalent metal ions in
order to be active and its DxD amino acid conserved domains
in which D stands for aspartic acid and x for any amino acid.
Polymerization reactions catalyzed by the recombinant
PmHS2 showed three distinct polymerization phases. PmHS2
initiates the polymerization process by the synthesis of short
oligosaccharides using nucleotide sugars. For PmHS2, the
initiation phase has been described to have a slow “de novo”
initiation rate (Sismey-Ragatz et al. 2007). We demonstrated
that for PmHS2, the nucleotide sugar concentrations during
the initiation phase play an important role in the average Mw
Fig. 6 Analysis of PmHS2 polymerization process in time. The
PmHS2 (55–60 μg/ml) enzymatic activity, incubated during 28 h at
30°C, was analyzed with standard assay conditions as described in the
Materials and methods section. At many time points, the amount of
substrate converted was determined using the coupled enzyme assay. a
The specific activity for the elongation phase (2–12 h) and the level
off were, respectively, 0.100±0.010 nmol/μg/min and 0.020±
0.005 nmol/μg/min. Five independent experiments were completed
for each data set, and their average±SD is presented. b The molecular
weight distribution of heparosan polymer in the samples was analyzed
by 2% agarose gels stained with Stains-All
Fig. 7 Effect of initial UDP concentration on PmHS2 activity.
Purified PmHS2 (55–60 μg/ml) was assayed in the standard
polymerization buffer described in the Materials and methods section
with increasing initial UDP concentrations from 0 to 10 mM. a The
nucleotide sugar concentration of both UDP-GlcUA and UDP-
GlcNAc was, respectively, 5 mM (○) and 20 mM (•). After 24 h of
incubation at 30°C, the amount of substrate converted by PmHS2 in
presence of UDP was determined using the coupled enzyme assay. b
Samples from both series were analyzed on a 2% agarose gel stained
with Stains-All
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and the polydispersity of the resulting heparosan polymers.
Low substrate concentrations favor the formation of higher
molecular weight polymers with a lower polydispersity
while high substrate concentrations do the opposite.
On one hand, we assume that, in an early stage of the
polymerization, the PmHS2 enzyme has more affinity for
oligomers than for nucleotide sugars. On the other hand, we
also hypothesize that, in presence of a low substrate
concentration, the probability for PmHS2 to encounter a
synthesized heparosan oligomers instead of a nucleotide
sugar is relatively high. A lower substrate concentration
causes less heparosan chains to be initiated. Consequently,
lesser heparosan polymers to be elongated, and thus, it will
result in the synthesis of longer heparosan polymer chains.
This polymerization phenomenon is similar to what has
been observed with PmHAS and PmHS1 in presence of
oligosaccharide acceptors. For both enzymes, the affinity
for the oligosaccharide acceptor was higher than for
activated monosaccharides. In addition, a decrease in
oligosaccharide acceptor concentration resulted in polymer
chains with a higher Mw, while an increase in acceptor
lowered the average Mw of the polymer formed (Jing and
DeAngelis 2004; Sismey-Ragatz et al. 2007). We demon-
strated that for PmHS2, the initiation is a determinant step
in the polymer synthesis. During this phase, the amount of
heparosan chains initiated is regulated by the nucleotide
sugar concentration. Another conclusion from this experi-
ment is that PmHS2 is a nonprocessive enzyme. With a
processive enzyme, the dissociation of the polymer and the
enzyme implicates the end of the chain elongation. The
amount of chains initiated will not differ depending on the
nucleotide sugar concentrations, and thus, low substrate
concentrations will result in shorter polysaccharides. At the
opposite, with a nonprocessive enzyme such as PmHS2, the
addition of a single monosaccharide to the growing chain is
followed by the dissociation of the polymer from the
enzyme. The polymer is recaptured before proceeding to
the transfer of new monosaccharide unit. As in presence of
low substrate concentration, PmHS2 initiates less chains,
and it leads to higher molecular weight products.
The substrate concentration also influenced the specific
activity of the PmHS2 enzyme during the elongation phase.
The highest activity was observed by adding 5 mM of each
UDP-sugars, from 3 to 6 h of incubation, and the specific
activity was found to be about 0.145±0.010 nmol/µg/min. In
this research, the specific activity observed for PmHS2 is
considerably higher than the elongation rate of 28 pmol/μg/min
that has been reported so far for PmHS2 (Sismey-Ragatz
et al. 2007). When using the optimal nucleotide sugar
concentration, PmHS2 showed an elongation phase of
about 10 h, and under these conditions, the polymers
chains were elongated with average up to 500 to 550
monosaccharides units in 24 h.
Although we have observed that at the first stage of the
polymerization that the enzyme has more affinity towards
products with a higher molecular weight, both the elonga-
tion and the initiation of new heparosan chain occur
simultaneously. Weigel stipulated that despite the fact that,
in theory, nonprocessive enzyme could elongate the
polymer chains till infinite, it has not been observed. Due
to the increase of the polymer chain length and the polymer
concentration, interaction between the nonreducing end of
the polymer chains and the enzyme become more difficult
in time. As the system enzyme/polymer is becoming more
rigid, it will favor the initiation of new polymer chains from
nucleotide sugars or short oligosaccharides that are more
mobile than longer chains (Weigel 2002). This phenomenon
supports the fact that new heparosan chains are also
initiated while the elongation of polymer occurs. As newly
elongated heparosan oligomers cannot obtain the same
molecular weight as the previously synthesized heparosan
polymers during the incubation time, it results in a broader
molecular weight distribution and therefore, a higher
polydispersity.
In many studies, UDP was found to be an inhibitor of
glycosyltransferase activity (Baggenstoss and Weigel 2006;
Markovitz et al. 1959; Stoolmiller and Dorfman 1969;
Tlapak-Simmons et al. 2004). PmHS2 also is inhibited by
UDP. The UDP inhibition is influenced by the nucleotide
sugar concentration, and high substrate concentrations
reduce the UDP inhibition. We observed that the specific
activity of PmHS2 remained constant during the incubation
period from 2 to 12 h, despite the decrease of available
nucleotide sugars and the subsequent increase in UDP. This
showed that the UDP concentration present in the poly-
merization assay has to reach a certain concentration limit
which seems to be above 4 mM in order to be an inhibitor
of PmHS2 activity.
To summarize, we observed that purified PmHS2 is able
to synthesize relatively long heparosan polymers with an
Mw up to 130 kDa. In the presence of 5 mM of each UDP-
sugar, a maximal specific activity of 0.145 nmol/µg/min
was found. We showed evidence that a change in the initial
nucleotide sugar concentrations influenced the final product
molecular weight and polydispersity and confirmed that
PmHS2 is a nonprocessive enzyme. Future studies on
heparosan synthase will allow us to develop an in vitro
production system in which heparosan polymer chain
length can be controlled.
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